TrialThe Lancet. Infectious diseases2023

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.

Victor Kande Betu Kumeso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.